Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jason M Burkett"'
Publikováno v:
American Journal of Health-System Pharmacy.
Autor:
Neil T, Mason, Jason M, Burkett, Ryan S, Nelson, Julio M, Pow-Sang, Robert A, Gatenby, Timothy, Kubal, John W, Peabody, G Douglas, Letson, Howard L, McLeod, Jingsong, Zhang
Publikováno v:
Am Health Drug Benefits
BACKGROUND: The use of a novel strategy known as adaptive abiraterone therapy based on mathematical modeling of evolutionary dynamics of tumor subpopulations was shown in a clinical trial to extend the time to disease progression in patients with met
Autor:
Jason M Burkett, David Boulware, Karen K. Fields, Vasanth Kailasam, Karen A Sereday, Dana E. Rollison, Diane L. Blazevich, Julio M. Pow-Sang, JuQing Shi, Sandra C. Stewart, Peter A S Johnstone
Publikováno v:
Journal of Clinical Oncology. 37:20-20
20 Background: Moffitt Cancer Center (MCC) has developed evidence-based cancer care pathways which are integrated into the Electronic Health Record (EHR). We retrospectively compared the 1 year (yr) total cost of care in patients (pts) with newly dia
Autor:
Jason M Burkett, Howard L. McLeod, Douglas D. Letson, Neil Thomas Mason, Julio M. Pow-Sang, John W. Peabody, Robert A. Gatenby, Jingsong Zhang, Timothy Edward Kubal, Ryan Nelson
Publikováno v:
Journal of Clinical Oncology. 37:e18343-e18343
e18343 Background: We recently completed a study showing that adaptive abiraterone therapy (AT) led to more than a doubling of the time to radiographic progression (TTP) compared to continuous therapy (CT) in patients with metastatic castration resis
Autor:
Karen K. Fields, Cindy Terrano, Jason M Burkett, Bharat Rao, Marcos Salganicoff, Bharat Gorantla, Floyd Dukes
Publikováno v:
Journal of Clinical Oncology. 37:e18345-e18345
e18345 Background: Oncology providers are under mounting pressure to deliver high quality and increasingly complex cancer treatment while simultaneously managing the cost pressures coming from payers and patients alike. Developing an effective strate